Skip to main content
PMC home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2001 Apr;47:721–722.

Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.

E Kozer 1, M E Moretti 1, G Koren 1
PMCID: PMC2018413  PMID: 11340750

Abstract

QUESTION: I am treating a 34-year-old woman with rheumatoid arthritis. She began taking the new drug leflunomide (Arava) 6 months ago and had good clinical response. She is now planning her first pregnancy. What should she do? ANSWER: Leflunomide is a new and effective disease-modifying antirheumatic drug. Animal studies have shown an increased rate of malformations and fetal death in various species, but there are no data on pregnancy outcomes in humans treated with leflunomide. Since the drug has a prolonged and unpredictable elimination half-life, it should be stopped during pregnancy. The manufacturer recommends that patients who wish to become pregnant be treated with cholestyramine, which enhances elimination.

Full Text

The Full Text of this article is available as a PDF (25.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett R. R., Brendel S., Zielinski T., Schorlemmer H. U. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc. 1996 Dec;28(6):3074–3078. [PubMed] [Google Scholar]
  2. Cao W. W., Kao P. N., Aoki Y., Xu J. C., Shorthouse R. A., Morris R. E. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc. 1996 Dec;28(6):3079–3080. [PubMed] [Google Scholar]
  3. Chong A. S., Huang W., Liu W., Luo J., Shen J., Xu W., Ma L., Blinder L., Xiao F., Xu X. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation. 1999 Jul 15;68(1):100–109. doi: 10.1097/00007890-199907150-00020. [DOI] [PubMed] [Google Scholar]
  4. Emery P., Breedveld F. C., Lemmel E. M., Kaltwasser J. P., Dawes P. T., Gömör B., Van Den Bosch F., Nordström D., Bjorneboe O., Dahl R. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun;39(6):655–665. doi: 10.1093/rheumatology/39.6.655. [DOI] [PubMed] [Google Scholar]
  5. Fox R. I., Herrmann M. L., Frangou C. G., Wahl G. M., Morris R. E., Strand V., Kirschbaum B. J. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93(3):198–208. doi: 10.1006/clim.1999.4777. [DOI] [PubMed] [Google Scholar]
  6. Hamilton L. C., Vojnovic I., Warner T. D. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol. 1999 Aug;127(7):1589–1596. doi: 10.1038/sj.bjp.0702708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Janssen N. M., Genta M. S. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000 Mar 13;160(5):610–619. doi: 10.1001/archinte.160.5.610. [DOI] [PubMed] [Google Scholar]
  8. Jöckel J., Wendt B., Löffler M. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria. Biochem Pharmacol. 1998 Oct 15;56(8):1053–1060. doi: 10.1016/s0006-2952(98)00131-2. [DOI] [PubMed] [Google Scholar]
  9. Kremer J. M. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1999 Aug;29(1):14–26. doi: 10.1016/s0049-0172(99)80034-1. [DOI] [PubMed] [Google Scholar]
  10. Manna S. K., Aggarwal B. B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999 Feb 15;162(4):2095–2102. [PubMed] [Google Scholar]
  11. Mroczkowski P. J., Weinblatt M. E., Kremer J. M. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol. 1999 Nov-Dec;17(6 Suppl 18):S66–S68. [PubMed] [Google Scholar]
  12. Sharp J. T., Strand V., Leung H., Hurley F., Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000 Mar;43(3):495–505. doi: 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  13. Smolen J. S., Kalden J. R., Scott D. L., Rozman B., Kvien T. K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 Jan 23;353(9149):259–266. doi: 10.1016/s0140-6736(98)09403-3. [DOI] [PubMed] [Google Scholar]
  14. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov 22;159(21):2542–2550. doi: 10.1001/archinte.159.21.2542. [DOI] [PubMed] [Google Scholar]
  15. Yeh L. S., Gregory C. R., Griffey S. M., Lecouteur R. A., Morris R. E. Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat. Transplantation. 1996 Sep 27;62(6):861–863. doi: 10.1097/00007890-199609270-00027. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES